{
   "sha": "9b49622e8c16b0e941616d09e9ccdcfbc5d5ff0c",
   "source_x": "PMC",
   "title": "Graft-vs-tumor effect in patients with advanced nasopharyngeal cancer treated with nonmyeloablative allogeneic PBSC transplantation",
   "doi": "http://dx.doi.org/10.1038/bmt.2010.161",
   "pmcid": "PMC3072519",
   "pubmed_id": "20661236",
   "license": "CC BY-NC-ND",
   "abstract": "While nonmyeloablative peripheral blood stem cell transplantation (NST) has shown efficacy against several solid tumors, it is untested in nasopharyngeal cancer (NPC). In a phase II clinical trial, 21 patients with pretreated metastatic NPC underwent NST with sibling PBSC allografts, using CY conditioning, thymic irradiation and in vivo T-cell depletion with thymoglobulin. Stable lymphohematopoietic chimerism was achieved in most patients and prophylactic CYA was tapered at a median of day +30. Seven patients (33%) showed partial response and three (14%) achieved stable disease. Four patients were alive at 2 years and three showed prolonged disease control of 344, 525 and 550 days. With a median follow-up of 209 (4\u20131147) days, the median PFS was 100 days (95% confidence interval (CI), 66\u2013128 days), and median OS was 209 days (95% CI, 128\u2013236 days). Patients with chronic GVHD had better survival\u2014median OS 426 days (95% CI, 194\u2013NE days) vs 143 days (95% CI, 114\u2013226 days) (P=0.010). Thus, NST may induce meaningful clinical responses in patients with advanced NPC.",
   "publish_time": "2011 Apr 26",
   "authors": [
      "['Toh, H C', 'Chia, W K', 'Sun, L', 'Thng, C H', 'Soe, Y', 'Phoon, Y P', 'Yap, S P', 'Lim, W T', 'Tai, W M', 'Hee, S W', 'Tan, S H', 'Leong, S S', 'Tan, E H']"
   ],
   "journal": "Bone Marrow Transplant",
   "has_full_text": "True",
   "id": "9b49622e8c16b0e941616d09e9ccdcfbc5d5ff0c",
   "fhir_link": "Non-comercial/9b49622e8c16b0e941616d09e9ccdcfbc5d5ff0c"
}